A Study of PEG-somatropin in the Treatment of Children With Idiopathic Short Stature
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study aims to explore the optimal dose of pegylated recombinant human growth hormone
(PEG-rhGH) injection to treat children with idiopathic short stature (ISS), evaluate its
safety and efficacy, and provide scientific and reliable evidence for the medication dosage
in Phase III clinical study.
Phase:
Phase 2
Details
Lead Sponsor:
GeneScience Pharmaceuticals Co., Ltd.
Collaborators:
Affiliated Hospital of Jiangnan University Children's Hospital of Fudan University First Hospital of Jilin University Shanghai Children's Hospital The Children's Hospital of Zhejiang University School of Medicine The First Affiliated Hospital with Nanjing Medical University The First Hospital of Jilin University Tongji Hospital